InsidersTradesSigma
Follow the Sight Sciences, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sight Sciences, Inc. has recorded 189 reports. Market capitalisation: €471m. The latest transaction was reported on 4 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: HAYDEN JEREMY B.. All data is openly available.
189
Insider Decl.
n/a
Thresholds
€14m
21 ops.
Buy Volume
€20m
73 ops.
Sell Volume
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,751 of 29,062 companies
26.6
score / 100
Value19
Quality35
FCF yld-6.4%
Earn yld-8.2%
EV/EBITDA·
ROE-48%
Gross mgn86%
Net mgn-50%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations189 total
12,219 shares@ US$8.2876CommonSEC144:0001959173-26-006765
181,818 shares0Common StockSEC:0001193125-26-355783:0
12,014 shares@ US$8.1440.022% mcap6.7% of flowCommonSEC144:0001959173-26-006121
48,000 shares@ US$8.24750.086% mcap29.1% of flowCommonSEC144:0001959173-26-006045
2,500 shares@ US$8.3050.0045% mcap2.2% of flowCommonSEC144:0001959173-26-005984
16,302 shares@ US$8.17730.031% mcap14.1% of flowCommonSEC144:0001959173-26-005935
20,918 shares@ US$7.92990.039% mcap20.5% of flowCommonSEC144:0001959173-26-005895
7,418 shares@ US$5.50790.0092% mcap12.9% of flowCommonSEC144:0001959173-26-005125
12,733 shares@ US$5.50790.016% mcap15.3% of flowCommonSEC144:0001959173-26-005124
7,418 shares@ US$5.5080.0092% mcap18.1% of flowCommon StockSEC:0001193125-26-296594:0
24,184 shares@ US$5.360.029% mcap24.7% of flowCommon StockSEC:0001193125-26-296590:0
28,684 shares@ US$5.420.035% mcap14.9% of flowCommon StockSEC:0001193125-26-296589:0
2,829 shares@ US$5.420.0035% mcap1.9% of flowCommon StockSEC:0001193125-26-296593:0
12,733 shares@ US$5.5080.016% mcap20.4% of flowCommon StockSEC:0001193125-26-296597:0
6,902 shares@ US$5.360.0084% mcap100.0% of flowCommon StockSEC:0001193125-26-296596:0
24,184 shares@ US$5.35490.029% mcap17.4% of flowCommonSEC144:0001959173-26-005093
6,902 shares@ US$5.35490.0083% mcap37.2% of flowCommonSEC144:0001959173-26-005098
28,684 shares@ US$5.41680.035% mcap10.2% of flowCommonSEC144:0001959173-26-005034
2,829 shares@ US$5.41680.0035% mcap1.6% of flowCommonSEC144:0001959173-26-005035
14,100 sharesCommon StockSEC:0001193125-26-267752:0
Canonical exit: 8 Sept 2026 (T+90)
28,261 shares0Common StockSEC:0001193125-26-259565:0
28,261 shares0Common StockSEC:0001193125-26-259570:0
7,231 shares@ US$3.5540.7% of flowCommon StockSEC:0001193125-26-149858:0
13,761 shares@ US$3.5512.3% of flowCommon StockSEC:0001193125-26-149856:0
8,168 shares@ US$3.4811.1% of flowCommon StockSEC:0001193125-26-142233:0
25 of 189 declarations
关于 Sight Sciences, Inc.
Sight Sciences, Inc. (股票代码: SGHT) 是一家总部位于美国的眼科医疗技术公司，在美国纳斯达克市场上市。该公司于2010年在特拉华州注册成立，总部位于加利福尼亚州门洛帕克，其核心业务围绕介入性眼科护理技术，旨在改善青光眼和干眼症的治疗途径。其商业模式是专业的医疗技术平台，而非广泛的医疗设备特许经营。 Sight Sciences 通过两个核心商业领域运营。外科青光眼部门以 OMNI 系列产品为核心，包括 OMNI 和较新的 OMNI Edge 系统，这些产品专为微创青光眼手术 (MIGS) 设计。这些设备旨在通过解决眼睛的常规流出途径来降低眼内压。干眼症部门则以 TearCare 为中心，这是一种基于热疗的治疗系统，用于治疗与睑板腺功能障碍相关的干眼症，以及相关的耗材和配件。这为公司在眼科领域提供了两个独特但互补的增长方向。 从竞争角度来看，Sight Sciences 在高度监管的市场中瞄准具有临床意义的利基市场。其定位取决于产品创新、医生采纳、证据生成和报销进展。在青光眼领域，该公司在 MIGS 类别中与大型眼科和医疗技术公司竞争；在干眼症领域，它面临基于手术和基于药物的替代方案。管理层一直强调临床数据、同行评审出版物和健康经济支持是推动采纳和市场准入的关键杠杆。对于投资者而言，这意味着公司的商业轨迹与医生、支付方和医院采纳其程序的速度密切相关。 从地理上看，Sight Sciences 主要专注于美国，美国是其主要的商业市场和运营基地。其商标和产品开发具有更广泛的影响力，但收入产生仍集中在国内。公司不打算支付现金股息，而是将可用资本再投资于产品开发、商业化和报销计划。 最近的发展主要集中在 OMNI Edge 的推出、持续努力在 MIGS 领域建立商业势头，以及推动为 TearCare 争取更有利的报销。在2025年，管理层在季度更新中强调了这些优先事项，公司2026年全年业绩显示，年末季度收入适度复苏，同时调整后的运营费用有所降低。对于国际股票投资者而言，SGHT 最好被视为一个在纳斯达克上市的美国眼科医疗技术故事，具有显著的上涨潜力，但也对报销政策、程序采纳率和执行风险敏感。
